La vendita allo scoperto per Allurion Technologies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Allurion Technologies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Allurion Technologies (NYSE:ALUR) Azioni, Report sulle vendite allo scoperto

Allurion Technologies

Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Allurion Technologies Inc

Allurion Technologies, Inc. Warrants, each whole warrant exercisable to purchase 1.420455 shares of common stock at an exercise price of $8.10 per share of common stock

RBC Capital analyst Maurice Choy reiterates Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Sector Perform and maintains C$65 price target.

News

Price Target

Reiteration

Analyst Ratings

TSX:FTS

RBC Capital Reiterates Sector Perform on Fortis, Maintains C$65 Price Target

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $160 to $171.

MASI

Wells Fargo Maintains Overweight on Masimo, Raises Price Target to $171

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 1,200 points on Wednesday.
The Dow traded up 2.90% to 43,445.79 while the NASDAQ rose 2.03% to 18,813.03. The S&amp;P 500 also rose, gaining, 1.77% to 5,884.97.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/11/41774936/how-to-earn-500-a-month-from-qualcomm-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 4.4% on Tuesday.
In trading on Tuesday, real estate shares fell by 1.8%.
Top Headline
Former President Donald Trump declared victory in the 2024 presidential election after winning the key battleground states.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares shot up 171% to $0.3718.</li>
<li>Shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) got a boost, surging 110% to $8.82 after the company announced the issuance of a U.S. patent covering an IL-18 variant into two novel immunotherapeutic drug candidates.</li>
<li>Trilogy Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#NYSE">TMQ</a>) shares were also up, gaining 73% to $0.9835.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares dropped 42% to $4.12.</li>
<li>Shares of Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) were down 40% to $7.94 after the company announced the pricing of $9.15 million private placement.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) was down, falling 35% to $19.14 after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $71.50 while gold traded down 2.8% at $2,672.20.
Silver traded down 4.8% to $31.215 on Wednesday, while copper fell 4.6% to $4.2690.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX dipped 1.2% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 3.1%, while London's FTSE 100 fell 0.3%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 gaining 2.61%, Hong Kong's Hang Seng Index falling 2.23%, China's Shanghai Composite Index falling 0.09% and India's BSE Sensex gaining 1.13%.
Economics
U.S. mortgage applications fell by 10.8% from the previous week in the week ended Nov. 1.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41773566/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FOXO

NOVA

PACS

SONN

ZCAR

Dow Jumps Over 1,200 Points; Donald Trump Wins White House

Wells Fargo analyst Stephen Baxter maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and raises the price target from $275 to $285.

Wells Fargo Maintains Overweight on Universal Health Servs, Raises Price Target to $285

RBC Capital analyst Greg Pardy maintains Imperial Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#TSX">IMO</a>) with a Sector Perform and raises the price target from C$99 to C$101.

TSX:IMO

RBC Capital Maintains Sector Perform on Imperial Oil, Raises Price Target to C$101

RBC Capital analyst Jimmy Shan maintains InterRent REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IIP#TSX">IIP</a>) with a Outperform and lowers the price target from C$16.5 to C$15.

TSX:IIP

TSX:IIP/UN

RBC Capital Maintains Outperform on InterRent REIT, Lowers Price Target to C$15

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)&nbsp;reported third-quarter sales of $95.43 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $92.75 billion</a>.&nbsp;
Total revenues increased 6.3%, primarily driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769047/cvs-health-corporation-reports-third-quarter-2024-results" rel="noreferrer noopener">Health Services segment</a>.
Adjusted EPS of $1.09 (inline with preliminary guidance of $1.05-$1.10) decreased from $2.21 in the prior year, missing the consensus of $1.53. The fall was primarily due to a decline in the Health Care Benefits segment&#8217;s operating results, which reflects continued utilization pressure and premium deficiency reserves of approximately $1.1 billion, related to anticipated losses in the fourth quarter of 2024 within the Medicare and individual <a target="_blank" href="https://www.benzinga.com/news/24/11/41719665/cvs-health-q3-earnings-preview-can-the-company-overcome-recent-challenges" rel="noreferrer noopener">exchange product lines</a>.
Adjusted operating income decreased 77.5% to $2.55 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms</a>
During the third quarter of 2024, CVS Health <a target="_blank" href="https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2024/Q3-2024-Earnings-Release.pdf" rel="noreferrer noopener">finalized</a> its restructuring plan and recorded restructuring charges of approximately $1.2 billion, including store impairment charges for additional retail pharmacy stores it plans to close in 2025.
Revenues in the Health Care Benefits segment increased 25.5% to $32.99 billion. The Medical benefit ratio increased to 95.2% from 85.7% a year ago. Medical membership reached 27.1 million.
Health Services segment revenues decreased 5.9% to $44.13 billion. Pharmacy claims processed decreased 16.5%.
Concurrently, CVS&nbsp;Health announced&nbsp;that Prem&nbsp;Shah will be Group President and responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna. Both appointments are effective today.
Pharmacy &amp; Consumer Wellness segment revenues increased 12.3% to $32.42 billion, primarily driven by increased prescription volume, including increased contributions from vaccinations and pharmacy drug mix.
In October, CVS Health appointed David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398693/cvs-health-appoints-david-joyner-president-and-chief-executive-officer" rel="noreferrer noopener">ongoing financial struggles</a>.
The company also withdrew the 2024 guidance provided in the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">second-quarter earnings release</a>.
Price Action:&nbsp;CVS stock is up 11.30% at $61.60&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41754167/why-is-astrazeneca-stock-sinking-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is AstraZeneca Stock Sinking On Tuesday?</a></li>
</ul>
Image via Shutterstock

Large Cap

Guidance

Health Care

Movers

General

CVS Health Stock Jumps After Mixed Q3 Earnings, Takes $1.2 Billion Restructuring Charges Hit

RBC Capital analyst Irene Nattel maintains Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) with a Outperform and raises the price target from C$34 to C$35.

TSX:PET

RBC Capital Maintains Outperform on Pet Valu Hldgs, Raises Price Target to C$35

WIIM

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of US-listed Chinese stocks are trading higher after Donald Trump was elected president of the United States, which could raise concerns over potential tariffs and US-China tensions.

Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $195 to $205.

Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $205

Warren Buffett, one of the world&#8217;s most successful investors, has shared plenty of advice over his long career. But one <a href="https://www.benzinga.com/news/23/07/33245523/warren-buffetts-no-1-investing-rule-dont-lose-money-practical-advice-for-a-billionaire-but-can-regul">piece of advice</a> stands out as his top rule: &#8220;The first rule of investment is don&#8217;t lose money.&#8221; And if you ask about the second rule? &#8220;Don&#8217;t forget the first.&#8221; According to Buffett, that&#8217;s all you need to know.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">1. Warren Buffett "Rule no.1 is don't lose and the second rule is never forget rule 1." &#x1f410; <a href="https://t.co/x0hEOgxVJ4">pic.twitter.com/x0hEOgxVJ4</a>
&mdash; Oliver &#x7C; MMMT Wealth (CPA) (@MMMTwealth) <a href="https://twitter.com/MMMTwealth/status/1850983304167571542?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
It might sound simple — even a bit obvious. After all, who wants to lose money? But Buffett's point is more profound than it might first appear. <a href="https://www.benzinga.com/news/24/09/41091380/warren-buffet-tells-investors-to-give-up-on-me-vs-stock-approach-what-tells-you-whether-you-should-k">His investment philosophy</a> is about protecting what you already have. If you lose a big chunk of your investment, you need a huge return just to get back to where you started.&nbsp;
For example, when a stock drops by a big margin, it requires an even greater gain just to get back to its original value. It's much easier to prevent these kinds of losses in the first place than to claw your way back from them.&nbsp;
Of course, saying &#8220;don't lose money&#8221; is easier than actually following through, especially with the ups and downs of the stock market. But there are practical strategies investors can use to help follow Buffett&#8217;s rule.
See Also: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
You lower the chance of suffering a significant loss on any one investment by <a href="https://www.benzinga.com/money/how-to-diversify-your-portfolio">distributing your funds over several stocks or sectors</a>. Your portfolio can still be balanced even if one or two stocks do not perform well.
Buffett is known for investing in businesses with <a href="https://www.benzinga.com/startups/24/10/41252767/warren-buffetts-timeless-advice-is-to-invest-in-stocks-that-youd-be-perfectly-happy-to-hold-if-the-m">strong fundamentals</a> that he believes will be successful for many years to come. He prefers companies with a competitive edge, solid management, and products people will continue to buy. Instead of chasing the cheapest stocks, he looks for good companies at reasonable prices.
The market can be a rollercoaster, and emotions like fear or greed often cause people to make costly mistakes. Buffett's approach is to stay calm when others are panicking and to make decisions based on logic, not emotion.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
It's worth noting that even Warren Buffett has lost money, and he has been open about what he thinks are his biggest investment mistakes. He has also stated that one of his worst missteps was purchasing Berkshire Hathaway, a textile company that was initially in decline. Nevertheless, Buffett has been successful over the long term despite these setbacks because he is focused on limiting losses and learning from his mistakes.
<h2 class="wp-block-heading">Alternative Opinions</h2>
On the other hand, some investors think that taking measured risks, even at the expense of occasional losses, is a necessary component of attaining sizable returns, even if Buffett&#8217;s advice to avoid losses is generally accepted. <a href="https://www.benzinga.com/personal-finance/24/06/39360926/diversification-thats-for-idiots-mark-cuban-slams-warren-buffetts-investment-strategy-i-think-bu">Mark Cuban, for example, once said</a>, &#8220;Diversification, that&#8217;s for idiots&#8221; and that &#8220;buy and hold is a crock of s&#x2A;&#x2A;&#x2A;.&#8221;
Plus, startups, emerging technologies, and high-growth companies often come with higher risk but also the potential for substantial gains — something that Buffett's cautious approach might miss.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

'The First Rule Of Investment Is Don't Lose,' Says Warren Buffett. The Second Rule? Don't Forget The First — 'That's All The Rules'

In the current session, SBA Comms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is trading at $218.54, after a 4.30% drop. Over the past month, the stock fell by 7.45%, and in the past year, by 0.22%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1730906184_0.png" alt="Past Year Chart" />

<h3>A Look at SBA Comms P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
SBA Comms has a lower P/E than the aggregate P/E of 52.76 of the Specialized REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730906184_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

SBAC

P/E Ratio Insights for SBA Comms

BITF

CLSK

COIN

HIVE

MARA

RIOT

Shares of crypto-linked stocks are trading higher amid strength in Bitcoin, which reached an all-time high during the US presidential election.

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Equal-Weight and raises the price target from $395 to $400.

Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $400

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and lowers the price target from $43 to $30.

APLS

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $30

RBC Capital analyst Pammi Bir maintains BTB Real Estate Investment Trust (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTB#TSX">BTB</a>) with a Sector Perform and raises the price target from C$3.5 to C$3.75.

TSX:BTB

RBC Capital Maintains Sector Perform on BTB Real Estate Investment Trust, Raises Price Target to C$3.75

Wells Fargo analyst Elyse Greenspan maintains American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) with a Equal-Weight and lowers the price target from $77 to $76.

Wells Fargo Maintains Equal-Weight on American Intl Gr, Lowers Price Target to $76

On Tuesday, Exact Sciences Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of $0.20.</a>
The reported quarterly sales of $708.66 million missed the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results" rel="noreferrer noopener">estimate of $717.66 million</a>.
Screening revenue was $545 million, an increase of 15%, and Precision Oncology&#8217;s revenue was $164 million, an increase of 5% on a reported and core revenue basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">FDA Clears Exact Sciences&#8217; Next-Generation Colorectal Cancer Diagnostic Test</a>.
&#8220;While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; said Kevin Conroy, chairman and CEO.
Guidance: Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion.
The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion.
Precision Oncology sales are expected to be $650 million- $655 million, down from prior guidance of $655 million &#8211; $675 million.
The company expects 2024 Adjusted EBITDA of $310 million—$320 million, down from previous guidance of $335 million—$355 million.
William Blair notes that management attributed the lower-than-expected guidance primarily to challenges affecting the screening segment.
While these explanations are logical, they raise questions about why certain factors weren&#8217;t identified or addressed sooner. Management, however, took full responsibility and conveyed a sincere commitment to improving performance, the analyst writes.
Despite these hurdles, the analyst remains optimistic about revenue growth in 2025, highlighting several factors within the company&#8217;s control.
William Blair emphasizes that investors will likely want to see clear signs of improved execution and revenue growth resuming in 2025.
With shares trading down, the analyst writes that valuation is at a compelling long-term entry point.
Price Action: At last check on Wednesday, EXAS stock was down 28.50% at $51.16.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41753865/apollos-fee-related-earnings-growth-sets-it-apart-in-alternative-assets-says-goldma" target="_blank" rel="noreferrer noopener">Apollo&#8217;s Fee-Related Earnings Growth Sets It Apart in Alternative Assets, Says Goldman Sachs With Bullish EPS Forecast</a></li>
</ul>

Analyst Color

EXAS

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) shares <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">are trading lower on Wednesday.</a>
The company reported third-quarter adjusted earnings per share of 71 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769448/the-odp-corporation-announces-third-quarter-2024-results" rel="noreferrer noopener">missing the street view of $1.60.</a>
Quarterly sales of $1.780 billion, down 11% year-over-year, missed the analyst consensus of $1.820 billion.
The decrease in reported sales is largely related to lower sales in its Office Depot Division, primarily due to 53 fewer retail locations in service compared to the previous year and reduced transactions, as well as lower sales in its ODP Business Solutions Division.
&#8220;We&#8217;re leveraging our differentiated core strengths to pivot towards higher growth B2B opportunities, and we are beginning to see promising traction at both our ODP Business Solutions and Veyer Divisions,&#8221; said Gerry Smith, chief executive officer.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft" rel="noreferrer noopener">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a>
In the quarter under review, adjusted EBITDA was $62 million, compared to $138 million in the year-ago period.
As of September 28, ODP had total available liquidity of approximately $728 million, consisting of $192 million in cash and equivalents.
In a separate press release, the company announced a partnership with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769797/the-odp-corporation-embarks-on-a-new-10-year-1-5b-transformative-partnership-with-nationally-recog" rel="noreferrer noopener">nationally recognized strategic reseller</a>. This partnership, worth up to $1.5 billion spanning a 10-year period, will leverage the reseller provider&#8217;s expertise in creating custom, results-driven e-commerce solutions and the company&#8217;s extensive fulfillment centers and delivery network.
Outlook: ODP has <a target="_blank" href="https://www.theodpcorp.com/news-releases/news-release-details/odp-corporation-announces-second-quarter-2024-results" rel="noreferrer noopener">lowered </a>its full-year 2024 adjusted EPS guidance from a range of $4.25 &#8211; $5.00 to $3.10 &#8211; $3.80, below the $4.27 analyst estimate.
The company expects sales to be approximately $7 billion (prior view: at least $7 billion), compared to the $7.09 billion estimate.
Price Action: ODP shares are trading lower by 15.2% to $26.37 at last check Wednesday.
Photo via <a href="https://commons.wikimedia.org/wiki/File:Office_Depot_%284190699897%29.jpg">Wikimedia Commons</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy" target="_blank" rel="noreferrer noopener">Trump&#8217;s Historic Return: 7 Ways His Second Term Could Impact The US Economy</a></li>
</ul>

Office Depot's Parent Company ODP Slashes 2024 Outlook After Weak Q3 Earnings, Eyes B2B Pivot To Offset Retail Woes

Wells Fargo analyst Michael Brown maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $149 to $164.

Wells Fargo Maintains Overweight on Apollo Global Management, Raises Price Target to $164

Allurion Technologies (ALUR) has provided an announcement. Allurion Technologies, Inc. has been notified by the New York Stock Exchange (NYSE) that...

Allurion Technologies Faces NYSE Delisting Risk and Considers Remedies

The latest update is out from Allurion Technologies (ALUR). Allurion Technologies, Inc. has expanded its Board of Directors, appointing Keith Johns...

Allurion Technologies Appoints New Class III Director

Allurion Technologies ( ($ALUR) ) has provided an announcement. Allurion Technologies, Inc., a healthcare company focused on obesity treatments, ha...

Allurion Technologies Faces NYSE Compliance Hurdle

Allurion receives non-compliance notice from NYSE

Allurion Technologies (ALUR) has received a new Buy rating, initiated by Roth MKM analyst, Jason Wittes. Jason Wittes has given his Buy rating due ...

Innovative Weight Loss Solution and Strong Market Potential: A 'Buy' Rating for Allurion Technologies

Allurion started at buy by Roth MKM over weight-loss device potential

Josh Jennings, an analyst from TD Cowen, has initiated a new Buy rating on Allurion Technologies (ALUR). Josh Jennings has given his Buy rating due...

Innovative Product and Robust Business Model Fuel Buy Rating for Allurion Technologies

Allurion started at buy by Jefferies ahead of data for obesity therapy

Allurion Technologies (ALUR) announced the presentation of two abstracts at Obesity Week, the annual meeting of The Obesity Society. The first abst...

Allurion Technologies presents data at Obesity Week

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Allurion Technologies (ALUR – Research Report), with a price tar...

Allurion Technologies' Platform Shows Promising Weight Loss Results, Boosting Confidence in Commercial Potential

ALUR

Press Releases

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Coverage Initiation And Bullish Price Target Sends Micro Cap Flying

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Comments

Allurion Technologies

Vendite allo scoperto

Allurion Technologies (NYSE:ALUR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO